Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
Journal of Hepatology|November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutionsDavid Burger, David Back, Peter Buggisch, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.
Antiviral Therapy|June 3, 2010
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini, Luigia Elzi, Sara Gibbons, et al.
Plos One|August 8, 2013
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory studyJosé R Santos, José A Muñoz-Moreno, José Moltó, et al.
Pharmacogenetics and Genomics|January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphismMarco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
British Journal of Pharmacology|July 19, 2020
Safety perspectives on presently considered drugs for the treatment of COVID-19Sophie L Penman, Robyn T Kiy, Rebecca L Jensen, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.
The Journal of Antimicrobial Chemotherapy|February 10, 2012
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Violet Okaba-Kayom, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
Journal of Hepatology|November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutionsDavid Burger, David Back, Peter Buggisch, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.
Antiviral Therapy|June 3, 2010
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini, Luigia Elzi, Sara Gibbons, et al.
Plos One|August 8, 2013
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory studyJosé R Santos, José A Muñoz-Moreno, José Moltó, et al.
Pharmacogenetics and Genomics|January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphismMarco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
British Journal of Pharmacology|July 19, 2020
Safety perspectives on presently considered drugs for the treatment of COVID-19Sophie L Penman, Robyn T Kiy, Rebecca L Jensen, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous MeningitisSam Nightingale, Tran Thi Hong Chau, Martin Fisher, et al.
The Journal of Antimicrobial Chemotherapy|February 10, 2012
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Violet Okaba-Kayom, et al.
Pageof 15